Clinical Trial Update: Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing RAD001 (everolimus) with sunitinib as first-line and second-line therapy for metastatic renal cell carcinoma has completed and posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• Sutent (sunitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-06-28